Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide-1 (GLP-1) receptor agonist in women with obesity for frozen embryo transfer (FET): pragmatic, multicenter, randomized controlled trial

NCT ID NCT07811895

NEW Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 10, 2026

Summary

To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,510 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women aged 20-40 years; 2. Body Mass Index(BMI) ≥ 28kg/m2; 3. Women who intend to undergo frozen-thawed embryo transfer; 4. At least one embryo available for transfer; 5. Be capable of giving informed consent. Exclusion Criteria: 1. Women who have been diagnosed with diseases affecting uterine cavity or endometrial receptivity; 2. Presence of endocrine disorders that may significantly affect body weight; 3. Use of drugs that may cause significant weight changes within 8 weeks before screening; 4. Presence of contraindications to the use of dual GIP/GLP-1 receptor agonist; 5. Previous bariatric surgery (e.g., gastric bypass) or planning to undergo such surgery during the study period; 6. Serum triglycerides (TG) \> 5.64mmol/L; 7. Calcitonin≥50 ng/L; 8. Presence of medical contraindications to assisted reproductive technology and/or pregnancy; 9. Any other condition considered inappropriate for participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Frozen embryo transfer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Frozen embryo transfer Obesity Tirzepatide

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • RenJi Hospital

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.